Altynai Satylganova

Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial

Lone B Enebo, Kasper K. Berthelsen, Martin Kankam et al. · The Lancet · 2021 · 302 citations

Pharmacy, Pharmacokinetics, Pharmacology +7

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial

David C.W. Lau, Lars Erichsen, Ann Marie Ocampo Francisco et al. · The Lancet · 2021 · 242 citations · Full text

Agriculture, Nutrition, Pharmacotherapy +11

Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database

Christiane Lundegaard Haase, Anne Helene Olsen, Altynai Satylganova et al. · International Journal of Obesity · 2021 · 209 citations · Full text

Medicine, Chronic Disease Prevention, Disease Prevention +9

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial

W. Timothy Garvey, Andreas L. Birkenfeld, Dror Dicker et al. · Diabetes Care · 2020 · 181 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Body mass index and risk of obesity‐related conditions in a cohort of 2.9 million people: Evidence from a UK primary care database

Christiane Lundegaard Haase, Kirsten T. Eriksen, Altynai Satylganova et al. · Obesity Science & Practice · 2020 · 52 citations · Full text

Public Health, Internal Medicine, Clinical Epidemiology +12